{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:52:37Z","timestamp":1792723957297,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jval.2022.01.025","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T16:55:35Z","timestamp":1647622535000},"page":"1336-1343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies"],"prefix":"10.1016","volume":"25","author":[{"given":"Siyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Olchanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.01.025_bib1","series-title":"Cost-Effectiveness in Health and Medicine","author":"Weinstein","year":"1996"},{"issue":"10","key":"10.1016\/j.jval.2022.01.025_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974-2018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2022.01.025_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"7 suppl 1","key":"10.1016\/j.jval.2022.01.025_bib5","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/MLR.0b013e31819c9571","article-title":"Economic productivity by age and sex: 2007 estimates for the United States","volume":"47","author":"Grosse","year":"2009","journal-title":"Med Care"},{"issue":"46","key":"10.1016\/j.jval.2022.01.025_bib6","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1016\/j.vaccine.2021.09.070","article-title":"Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines","volume":"39","author":"Silver","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jval.2022.01.025_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1524-4733.2007.00205.x","article-title":"Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations","volume":"10","author":"Hughes","year":"2007","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2022.01.025_bib8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jval.2020.06.002","article-title":"Measuring \u201cfearonomic effects\u201d in valuing therapies: an application to COVID-19 in China","volume":"23","author":"Ma","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.01.025_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpubeco.2016.11.012","article-title":"The insurance value of medical innovation","volume":"145","author":"Lakdawalla","year":"2017","journal-title":"J\u00a0Public Econ"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","article-title":"How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies","volume":"31","author":"Lakdawalla","year":"2012","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2013.814948","article-title":"Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents","volume":"13","author":"Lin","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2022.01.025_bib12","author":"Philipson"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/13571516.2011.584428","article-title":"Real option value and path dependence in oncology innovation","volume":"18","author":"Cook","year":"2011","journal-title":"Int J Econ Bus"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jval.2019.02.002","article-title":"How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma","volume":"22","author":"Li","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hec.3899","article-title":"Do cancer treatments have option value? Real-world evidence from metastatic melanoma","volume":"28","author":"Li","year":"2019","journal-title":"Health Econ"},{"issue":"11 suppl","key":"10.1016\/j.jval.2022.01.025_bib16","first-page":"S265","article-title":"The option value of innovative treatments in the context of chronic myeloid leukemia","volume":"18","author":"Sanchez","year":"2012","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jhealeco.2004.12.002","article-title":"Implications of spillover effects within the family for medical cost-effectiveness analysis","volume":"24","author":"Basu","year":"2005","journal-title":"J\u00a0Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40273-019-00782-9","article-title":"Quantifying family spillover effects in economic evaluations: measurement and valuation of informal care time","volume":"37","author":"Grosse","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40258-014-0079-8","article-title":"Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill","volume":"12","author":"Lavelle","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib20","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jval.2022.01.025_bib22","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1377\/hlthaff.2016.0462","article-title":"Modeling the economic burden of adult vaccine-preventable diseases in the United States","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"10.1016\/j.jval.2022.01.025_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1634\/theoncologist.2010-0005","article-title":"Economic burden for informal caregivers of lung and colorectal cancer patients","volume":"15","author":"Van Houtven","year":"2010","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jval.2022.01.025_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature","volume":"23","author":"Insinga","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"18 Suppl","key":"10.1016\/j.jval.2022.01.025_bib25","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1002\/cncr.24588","article-title":"Time costs associated with informal caregiving for cancer survivors","volume":"115","author":"Yabroff","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2022.01.025_bib26","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.bbmt.2020.06.015","article-title":"Caregivers\u2019 out-of-pocket expenses and time commitment following hematopoietic stem cell transplantation at a rural cancer center","volume":"26","author":"Meehan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib27","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.3747\/co.25.3765","article-title":"Real-world patient- and caregiver-reported outcomes in advanced breast cancer","volume":"25","author":"Lambert-Obry","year":"2018","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.01.025_bib28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1186\/s12885-018-4855-y","article-title":"Health utility scores of family caregivers for leukemia patients measured by EQ-5D-3L: a cross-sectional survey in China","volume":"18","author":"Yu","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.01.025_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/0272989X14541328","article-title":"Measuring family HRQoL spillover effects using direct health utility assessment","volume":"35","author":"Prosser","year":"2015","journal-title":"Med Decis Making"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib31","first-page":"1","article-title":"United States life tables, 2010","volume":"63","author":"Arias","year":"2014","journal-title":"Natl Vital Stat Rep"},{"issue":"9","key":"10.1016\/j.jval.2022.01.025_bib32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1634\/theoncologist.2018-0019","article-title":"Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin\u2019s lymphoma","volume":"24","author":"Reyes","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jval.2022.01.025_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s41669-020-00204-z","article-title":"Cost-effectiveness analyses, costs and resource use, and health-related quality of life in patients with follicular or marginal zone lymphoma: systematic reviews","volume":"4","author":"Monga","year":"2020","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.jval.2022.01.025_bib36","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib37","doi-asserted-by":"crossref","first-page":"20122005","DOI":"10.1515\/1558-9544.1306","article-title":"The option value of innovation","volume":"15","author":"Thornton Snider","year":"2012","journal-title":"Forum Health Econ Policy"},{"key":"10.1016\/j.jval.2022.01.025_bib38","author":"Bell"},{"issue":"7","key":"10.1016\/j.jval.2022.01.025_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2022.01.025_bib43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pon.1820","article-title":"Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites","volume":"20","author":"Roelen","year":"2011","journal-title":"Psychooncology"},{"issue":"12","key":"10.1016\/j.jval.2022.01.025_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2008.253","article-title":"Quality of life and social integration after allogeneic hematopoietic SCT","volume":"42","author":"Bieri","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jval.2022.01.025_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/0284186X.2015.1125015","article-title":"Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation","volume":"55","author":"Kiserud","year":"2016","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.jval.2022.01.025_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdf031","article-title":"Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation","volume":"13","author":"Hensel","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jval.2022.01.025_bib47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10198-019-01098-3","article-title":"Variation in the methodological approach to productivity cost valuation: the case of prostate cancer","volume":"20","author":"Hanly","year":"2019","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.01.025_bib48","first-page":"17","article-title":"Humanistic and economic burden among caregivers of patients with cancer in Japan","volume":"23","author":"Ohno","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2022.01.025_bib49","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00520-014-2122-6","article-title":"Quantifying the burden of informal caregiving for patients with cancer in Europe","volume":"22","author":"Goren","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jval.2022.01.025_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14737167.2015.1102633","article-title":"The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology","volume":"15","author":"Olchanski","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2022.01.025_bib51","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","article-title":"The influence of time horizon on results of cost-effectiveness analyses","volume":"17","author":"Kim","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2022.01.025_bib52","series-title":"Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs","author":"Cookson","year":"2020"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T18:12:59Z","timestamp":1728929579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522001036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1098301522001036"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.01.025","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}